SUBSCRIPTION AGREEMENT COMMON STOCK DENALI CONCRETE MANAGEMENT INC.Subscription Agreement • September 10th, 2013 • Can-Fite BioPharma Ltd. • Pharmaceutical preparations • Nevada
EMPLOYMENT AND NON-COMPETITION AGREEMENTEmployment Agreement • September 10th, 2013 • Can-Fite BioPharma Ltd. • Pharmaceutical preparations • Tel-Aviv
This Employment Agreement (“Agreement”) dated June 10, 2003, effective as of an employment starting date to be decided between the parties and that will occur not later than September 1, 2003 (“Effective Date”), by and between Can-Fite Biopharma Ltd., an Israeli company with its principal offices in 10 Bareket Street, Petach Tikva, Israel, (the “Company”), and Moti Farbstein (I.D. Number: 057682205), an individual whose address is 22 Degania Street, Ganei Tikva (the “Employee”).
LICENSE AGREEMENTLicense Agreement • September 10th, 2013 • Can-Fite BioPharma Ltd. • Pharmaceutical preparations
This License Agreement (this “Agreement”), dated November 21, 2011 (the “Effective Date”), is made by and between CAN-FITE Biopharma Ltd., a public company incorporated under the laws of the State of Israel (“CANFITE”), and Eye-Fite Ltd., a private company incorporated under the laws of the State of Israel (“EYEFITE”). CANFITE and EYEFITE are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties.”
SERVICES AGREEMENTServices Agreement • September 10th, 2013 • Can-Fite BioPharma Ltd. • Pharmaceutical preparations
THIS SERVICES AGREEMENT (the “Agreement”) made as of this 21 day of November, 2011 (the “Effective Date”) by and between CAN-FITE BIOPHARMA LTD., an Israeli-registered public company whose principal place of business is located at 10 Bareket Street, Petach Tikva, Israel ( “CanFite”), DENALI CONCRETE MANAGEMENT INC., a Nevada-registered company, whose principal place of business is located at 123 West Nye Lane, Suite 129, Carson City, NV 89706 (“Denali”), USA and its wholly owned subsidiary, EYEFITE LTD., an Israeli-registered private company whose principal place of business is located at 12 Abba Hillel Silver, Ramat Gan 52506, Israel (“EyeFite”; Denali and EyeFite collectively, the “Company”)
PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT—EXCLUSIVE COVER PAGEPatent License Agreement • September 10th, 2013 • Can-Fite BioPharma Ltd. • Pharmaceutical preparations • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) and/or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Modifications), Appendix E (Benchmarks), and Appendix F (Commercial Development Plan). The Parties to this Agreement are:
RE: Reimbursement for the Costs of the Clinical TrialService Agreement • September 10th, 2013 • Can-Fite BioPharma Ltd. • Pharmaceutical preparations
Further to the Service Agreement entered into between Can Fite Biopharma Ltd. (“Canfite”), Eyefite Ltd. and OphthaliX Inc. (Eyefite Ltd. and OphthaliX Inc. shall be collectively referred herein as the “Company”) dated November 22, 2011 (the “Agreement”), Canfite hereby agrees to defer receiving payments owed under the Agreement from January 31, 2013 for the performance of the clinical trials of CF101 in ophthalmic indications until the completion of a fundraising in the Company (or any other financing of the Company by way of joint venture, out-licensing or any other collaboration) (the ” Financing”). In any event, upon the occurrence of such Financing, Canfite will not require the payment of any outstanding balance, in excess of the available cash of the Company after the fulfillment of its obligations to other creditors at that time. Any such deferred payments shall bear interest at a rate of 3% per annum from the due date of each invoice issued by Can-Fite to OphthaliX or EyeFite un
SERVICE MANAGEMENT AGREEMENTService Management Agreement • September 10th, 2013 • Can-Fite BioPharma Ltd. • Pharmaceutical preparations
THIS AGREEMENT is between Can-Fite Biopharma Ltd., an Israeli company, whose address is 10 Bareket Street, Petach Tikva, Israel (the “Company”) and F.D. Consulting International and Marketing Ltd., an Israeli company, whose address is City Gate Building, Ben Gurion Street, Herzliya, Israel. (“Manager”), for services as hereinafter provided is entered as of June 27 2002 (“Effective Date”).
LICENSE AGREEMENT BETWEEN CAN-FITE BIOPHARMA, LTD. AND SEIKAGAKU CORPORATION DATED September 22, 2006License Agreement • September 10th, 2013 • Can-Fite BioPharma Ltd. • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”), dated as of September 22, 2006 (the “Effective Date”), is made by and between Can-Fite BioPharma, Ltd., having its principal place of business at 10 Bareket St. Petach Tikva, Israel (“Can-Fite”), and Seikagaku Corporation, having its principal place of business 6-1, Marunouchi 1-chome, Chiyoda-ku, Tokyo 100-0005, Japan (“SKK”). Can-Fite and SKK may be referred to herein individually as a “Party” and collectively as the “Parties.”
